Multidisciplinary Clinical Approach to Cancer Patients with Immune-Related Adverse Events Induced by Checkpoint Inhibitors

Autor Londoño, Maria-Carlota, Reig, Maria
Vydáno v Cancers (Basel) (2020)

The success of regorafenib in hepatocellular carcinoma in a world of failures. Learnings for future developments

Autor Reig, Maria, Díaz-González, Álvaro, Bruix, Jordi
Vydáno v Oncotarget (2017)

Natural history and staging for hepatocellular carcinoma

Autor Forner, Alejandro, Rodríguez‐Lopez, Carlos, Reig, María
Vydáno v Clin Liver Dis (Hoboken) (2013)

Evolución natural y estratificación del carcinoma hepatocelular

Autor Forner, Alejandro, Rodríguez‐López, Carlos, Reig, María
Vydáno v Clin Liver Dis (Hoboken) (2013)

Systemic therapy for hepatocellular carcinoma: trial enrichment does not guarantee success

Autor Da Fonseca, Leonardo G., Reig, Maria, Bruix, Jordi
Vydáno v Oncotarget (2018)

Hepatocellular Carcinoma Recurrence in HCV Patients Treated with Direct Antiviral Agents

Autor Sanduzzi-Zamparelli, Marco, Boix, Loreto, Leal, Cassia, Reig, María
Vydáno v Viruses (2019)

HEPATOCELLULAR CARCINOMA: NOVEL MOLECULAR APPROACHES FOR DIAGNOSIS, PROGNOSIS AND THERAPY

Autor Villanueva, Augusto, Minguez, Beatriz, Forner, Alejandro, Reig, Maria, Llovet, Josep M.
Vydáno 2010

Approach of the patient with a liver mass

Autor Rodríguez de Lope, Carlos, Reig, María E, Darnell, Anna, Forner, Alejandro
Vydáno v Frontline Gastroenterol (2012)

Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma

Autor Sangro, Bruno, Chan, Stephen L., Meyer, Tim, Reig, María, El-Khoueiry, Anthony, Galle, Peter R.
Vydáno v J Hepatol (2020)

Controversies in the management of hepatocellular carcinoma

Autor Forner, Alejandro, Da Fonseca, Leonardo G, Díaz-González, Álvaro, Sanduzzi-Zamparelli, Marco, Reig, María, Bruix, Jordi
Vydáno v JHEP Rep (2019)

The TGF-β Pathway: A Pharmacological Target in Hepatocellular Carcinoma?

Autor Gonzalez-Sanchez, Ester, Vaquero, Javier, Férnandez-Barrena, Maite G., Lasarte, Juan José, Avila, Matías A., Sarobe, Pablo, Reig, María, Calvo, Mariona, Fabregat, Isabel
Vydáno v Cancers (Basel) (2021)

Progression-Free Survival Early Assessment Is a Robust Surrogate Endpoint of Overall Survival in Immunotherapy Trials of Hepatocellular Carcinoma

Autor Cabibbo, Giuseppe, Celsa, Ciro, Enea, Marco, Battaglia, Salvatore, Rizzo, Giacomo Emanuele Maria, Busacca, Anita, Matranga, Domenica, Attanasio, Massimo, Reig, Maria, Craxì, Antonio, Cammà, Calogero
Vydáno v Cancers (Basel) (2020)

Regorafenib Alteration of the BCL-xL/MCL-1 Ratio Provides a Therapeutic Opportunity for BH3-Mimetics in Hepatocellular Carcinoma Models

Autor Cucarull, Blanca, Tutusaus, Anna, Subías, Miguel, Stefanovic, Milica, Hernáez-Alsina, Tania, Boix, Loreto, Reig, María, García de Frutos, Pablo, Marí, Montserrat, Colell, Anna, Bruix, Jordi, Morales, Albert
Vydáno v Cancers (Basel) (2020)

Antiapoptotic BCL-2 proteins determine sorafenib/regorafenib resistance and BH3-mimetic efficacy in hepatocellular carcinoma

Autor Tutusaus, Anna, Stefanovic, Milica, Boix, Loreto, Cucarull, Blanca, Zamora, Aynara, Blasco, Laura, de Frutos, Pablo García, Reig, Maria, Fernandez-Checa, Jose C., Marí, Montserrat, Colell, Anna, Bruix, Jordi, Morales, Albert
Vydáno v Oncotarget (2018)

Pattern of progression in advanced hepatocellular carcinoma treated with ramucirumab

Autor Reig, Maria, Galle, Peter R., Kudo, Masatoshi, Finn, Richard, Llovet, Josep M., Metti, Andrea L., Schelman, William R., Liang, Kun, Wang, Chunxiao, Widau, Ryan C., Abada, Paolo, Zhu, Andrew X.
Vydáno v Liver Int (2020)

Activated Lymphocytes and Increased Risk of Dermatologic Adverse Events during Sorafenib Therapy for Hepatocellular Carcinoma

Autor Corominas, Josep, Sapena, Victor, Sanduzzi-Zamparelli, Marco, Millán, Cristina, Samper, Esther, Llarch, Neus, Iserte, Gemma, Torres, Ferràn, Da Fonseca, Leonardo G., Muñoz-Martínez, Sergio, Forner, Alejandro, Bruix, Jordi, Boix, Loreto, Reig, María
Vydáno v Cancers (Basel) (2021)

Mutational profile of skin lesions in hepatocellular carcinoma patients under tyrosine kinase inhibition: a repercussion of a wide-spectrum activity

Autor da Fonseca, Leonardo G., Fuster-Anglada, Carla, Carrera, Cristina, Millán, Cristina, Samper, Esther, Sapena, Victor, Díaz-González, Álvaro, Sanduzzi-Zamparelli, Marco, Leal, Cassia, Forner, Alejandro, Bruix, Jordi, Reig, Maria, Boix, Loreto, Díaz, Alba
Vydáno v Oncotarget (2021)

Tumor biopsy and patient enrollment in clinical trials for advanced hepatocellular carcinoma

Autor Rimassa, Lorenza, Reig, Maria, Abbadessa, Giovanni, Peck-Radosavljevic, Markus, Harris, William, Zagonel, Vittorina, Pastorelli, Davide, Rota Caremoli, Elena, Porta, Camillo, Damjanov, Nevena, Patel, Hitendra, Daniele, Bruno, Lamar, Maria, Schwartz, Brian, Goldberg, Terri, Santoro, Armando, Bruix, Jordi
Vydáno v World J Gastroenterol (2017)

Early diarrhoea under sorafenib as a marker to consider the early migration to second‐line drugs

Autor Díaz‐González, Álvaro, Sapena, Víctor, Boix, Loreto, Torres, Ferrán, Sanduzzi‐Zamparelli, Marco, Da Fonseca, Leonardo G., LLarch, Neus, Iserte, Gemma, Guedes, Cassia, Muñoz‐Martínez, Sergio, Darnell, Anna, Belmonte, Ernest, Rimola, Jordi, Forner, Alejandro, Ayuso, Carmen, Bruix, Jordi, Reig, María
Vydáno v United European Gastroenterol J (2021)

Anti-miR-518d-5p overcomes liver tumor cell death resistance through mitochondrial activity

Autor Fernández-Tussy, Pablo, Rodríguez-Agudo, Rubén, Fernández-Ramos, David, Barbier-Torres, Lucía, Zubiete-Franco, Imanol, Davalillo, Sergio López de, Herraez, Elisa, Goikoetxea-Usandizaga, Naroa, Lachiondo-Ortega, Sofia, Simón, Jorge, Lopitz-Otsoa, Fernando, Juan, Virginia Gutiérrez-de, McCain, Misti V., Perugorria, Maria J., Mabe, Jon, Navasa, Nicolás, Rodrigues, Cecilia M. P., Fabregat, Isabel, Boix, Loreto, Sapena, Victor, Anguita, Juan, Lu, Shelly C., Mato, José M., Banales, Jesus M., Villa, Erica, Reeves, Helen L., Bruix, Jordi, Reig, Maria, Marin, Jose J. G., Delgado, Teresa C., Martínez-Chantar, María L.
Vydáno v Cell Death Dis (2021)